毕马威：2025年中国生命科学行业概览及未来展望报告（英文版）

Historically, life science companies experienced a decline in deal activity in 2020 due to theeconomic uncertainty and market volatilitycaused by the pandemic, which led to cautiousbehavior from investors and businesses, resulting in delayed deals and mergers. in contrast,2021 experienced a significant increase in deal activity, driven by heightened investorinterest in healthcare innovation, adaptation to virtual and remote transaction processes,and a strategic emphasis on expanding capabilit